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ABSTRACT
Introduction: The present study aimed to
describe characteristics of patients with type 2
diabetes (T2D) in UK primary care initiated on
dapagliflozin, post-dapagliflozin changes in
glycated hemoglobin (HbA1c), body weight
and blood pressure, and reasons for adding
dapagliflozin to insulin.
Methods: Retrospective study of patients with
T2D in the Clinical Practice Research Datalink
with first prescription for dapagliflozin. Patients
were included in the study if they: (1) had a
first prescription for dapagliflozin between
November 2012 and September 2014; (2) had a
Read code for T2D; (3) were registered with a
practice for at least 6 months before starting
dapagliflozin; and (4) remained registered for at
least 3 months after initiation. A questionnaire
ascertained reason(s) for adding dapagliflozin to
insulin.
Results: Dapagliflozin was most often used as
triple therapy (27.7%), dual therapy with
metformin (25.1%) or added to insulin
(19.2%). Median therapy duration was
329 days [95% confidence interval (CI)
302–361]. Poor glycemic control was the
reason for dapagliflozin initiation for 93.1% of
insulin-treated patients. Avoiding increases in
weight/body mass index and insulin resistance
were the commonest reasons for selecting
dapagliflozin versus intensifying insulin.
HbA1c declined by mean of 9.7 mmol/mol
(95% CI 8.5–10.9) (0.89%) 14–90 days after
starting dapagliflozin, 10.2 mmol/mol (95% CI
8.9–11.5) (0.93%) after 91–180 days and
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12.6 mmol/mol (95% CI 11.0–14.3) (1.16%)
beyond 180 days. Weight declined by mean of
2.6 kg (95% CI 2.3–2.9) after 14–90 days, 4.3 kg
(95% CI 3.8–4.7) after 91–180 days and 4.6 kg
(95% CI 4.0–5.2) beyond 180 days. In patients
with measurements between 14 and 90 days
after starting dapagliflozin, systolic and
diastolic blood pressure decreased by means of
4.5 (95% CI -5.8 to -3.2) and 2.0 (95% CI -2.9
to -1.2) mmHg, respectively from baseline.
Similar reductions in systolic and diastolic
blood pressure were observed after 91–180 days
and when follow-up extended beyond 180 days.
Results were consistent across subgroups.
Conclusion: HbA1c, body weight and blood
pressure were reduced after initiation of
dapagliflozin in patients with T2D in UK
primary care and the changes were consistent
with randomized clinical trials.
Funding: AstraZeneca.
Keywords: Blood pressure; Body weight;
Dapagliflozin; Diabetes; Glycated hemoglobin;
HbA1c
INTRODUCTION
Dapagliflozin, a selective sodium-glucose
co-transporter-2 inhibitor, reduces renal
glucose reabsorption, resulting in glycosuria,
improved glucose control, weight reduction
and blood pressure [1]. Placebo-controlled
randomized clinical trials (RCTs) and
comparator studies have shown that
dapagliflozin is effective in treatment-naı¨ve
patients with type 2 diabetes (T2D) [2, 3] as
well as add-on therapy for patients with
inadequate glycemic control while taking
metformin [1, 4–6], sitagliptin (with or
without metformin) [7], sulphonylurea (with
or without metformin) [8, 9] and insulin [10].
Dapagliflozin shows similar efficacy when used
as dual therapy with metformin or insulin,
and in triple therapy with other oral
glucose-lowering drugs [1, 4–8, 10, 11].
However, clinical trials are not necessarily
representative of the patient population treated
in routine care. For example, up to 39% of T2D
patients are ineligible based on age alone for
trials that have the most stringent inclusion and
exclusion criteria [12]. Observational studies
with minimal eligibility criteria allow the
assessment of use and outcomes in the wider
population and have stronger external validity.
This observational study aimed to describe the
characteristics of patients with T2D in primary
care in the UK who received their first
prescription for dapagliflozin. The study also
aimed to quantify the changes in glycated
hemoglobin (HbA1c), body weight and blood
pressure in patients after being initiated on
dapagliflozin and sought information on the
clinical reasons why the prescriber added
dapagliflozin to insulin and resulting changes
in insulin dose.
METHODS
The patient data for this retrospective
observational study were obtained from the
Clinical Practice Research Datalink (CPRD),
which contains anonymized longitudinal
patient records collected from more than 12
million patients across the UK [13]. Patients
were included in the study if they: (1) had a
first prescription for dapagliflozin between
November 2012 and September 2014; (2) had a
Read code for T2D (Supplementary material S1);
(3) were registered with a practice for at least
6 months before starting dapagliflozin; and (4)
remained registered for at least 3 months after
initiation. A questionnaire (Supplementary
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material S2) was sent to the general practices of
the subset of patients prescribed dapagliflozin as
add-on to insulin to ascertain the clinical reason
for prescribing dapagliflozin and the dose of
insulin before and after dapagliflozin initiation.
Statistical Methods
Eligible data were analyzed using descriptive
statistics. Changes in HbA1c, body weight
and systolic and diastolic blood pressure
were analyzed for those patients with a
measurement before receiving dapagliflozin
and at least one measurement during the year
after the first dapagliflozin prescription. Results
were grouped by time since dapagliflozin
initiation: 14–90 days; 91–180 days; and
[180 days (up to 365 days).
Baseline characteristics and follow-up
variables were described by frequency and
percentage distributions. Continuous and
count variables were given using mean
[±standard deviation (SD)], median (quartiles)
and 95% confidence intervals (CIs). All analyses
were performed using SAS version 9.2 (SAS
Institute, Inc., Cary, NC, USA).
Logistic regression models (reporting Odds
Ratios, ORs) were used to examine patient
characteristics associated with weight change
and achieving HbA1C targets. The model
included only measures recorded 14–365 days
after dapagliflozin initiation while patients were
on treatment. If patients had more than one
measure after dapagliflozin initiation, only the
first was examined.
Compliance with Ethics Guidelines
This was an observational, retrospective study
using anonymized data from CPRD, which
holds ethical approval for observational
studies. The Independent Scientific Advisory
Committee for Medicines and Healthcare
products Regulatory Agency (Protocol Number
14_236AMn) approved this study.
This article is based on observational data
and does not involve any new studies of human
or animal subjects performed by any of the
authors.
RESULTS
Patient Characteristics
Of 2401 patients who received at least one
prescription for dapagliflozin in the study
period, 1732 fulfilled the inclusion criteria
with sufficient follow-up (C3 months) to
enable description of co-prescribed medicines
(Fig. 1). HbA1c values were recorded for 1091
patients, body weight was recorded in 970 and
blood pressure in 851 patients before the first
prescription of dapagliflozin and during
dapagliflozin treatment.
The mean age of the patients (57.9% male)
included in the analysis was 57.5 (SD 10.5) years
(Table 1). At baseline, mean HbA1c was 80.1 (SD
17.9) mmol/mol (9.5%) and the mean weight
was 103.1 (SD 22.9) kg. The mean time since
T2D diagnosis was 9.5 (SD 6.0) years and 36.9%
of patients had a history of retinopathy, 20.4% a
history of neuropathy and 9.8% a history of
nephropathy.
Dapagliflozin Treatment
Within the first 3 months after initiation,
dapagliflozin was most commonly used as
triple therapy with other oral glucose-lowering
drugs (27.7% of dapagliflozin users), as dual
therapy with metformin (25.1%), or added to
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insulin (19.2%) (Fig. 1). In the 3 months, before
the first prescription for dapagliflozin, a wide
range of other oral diabetes medicines was
prescribed (Table 1). In patients who received
triple therapy (not shown in table), the most
common prior treatments were: metformin and
a dipeptidyl peptidase-4 (DPP-4) inhibitor
(21.5%); metformin and sulphonylurea
(19.8%); or metformin, sulphonylurea and
DPP-4 inhibitor (20.6%). In patients who
received dual therapy, the most common prior
treatments were: metformin monotherapy
(43.9%); metformin and DPP-4 inhibitor
(19.8%); or metformin and sulphonylurea
(11.7%). Most patients were initiated on 10 mg
dapagliflozin (86.1%), the remainder on 5 mg;
median duration of therapy was 10.8 months
(329.0 days; 95% CI 302.0–361.0).
Reasons for Adding Dapagliflozin
to Insulin
Additional information was requested from the
general practices for 217 patients who received
dapagliflozin as add-on to insulin. Of these, 145
questionnaires included some responses (66.8%
response rate), 23 questionnaires were returned
with no data, and 49 questionnaires were not
returned.
For most patients on insulin (93.1%), the
general practitioner (GP) reported that poor
glycemic control was the reason for dapagliflozin
initiation,with131requiringHbA1c improvement,
35 fasting glucose level improvement and 23
post-prandial glucose level improvement at
dapagliflozin initiation. GPs reported more than
one glycemic parameter for 40 patients.
Prescribed dapagliﬂozin 2401 Did not fulﬁl inclusion criteria 62      No type 2 diabetes recorded 1
> 6 months prior registraon 61
Eligible paents 2339
Oral only 1183 (68.3%)
Dual therapy 498 (28.8%)  
Injected therapy 549 (31.7%)  Add-on to insulin 332  
< 4 oral classes 1044 (60.3%)   
< 3 oral classes 564 (32.6%)    
Monotherapy 66 (03.8%) MET 435
SU 44
DPP-4 14
TZD 3
Other 2
Triple therapy 480 (27.7%) 
MET + SU 257
MET + DPP-4 179
SU + DPP-4 23
Fixed combinaon 11
MET + TZD 8
MET + Other 1
SU + TZD 1 
Dual MET 435
≥4 oral classes 139 (08.0%)    
≥ 3 months follow-up 1732 (74.0%)
< 3 months follow-up  607 (26.0%)
Treatment pattern 3 months post initiation of dapagliflozin
INSULIN 361      
GLP-1 126
INSULIN + GLP-1 62
Fig. 1 Disposition of patients. Met metformin, SU sulphonylurea, DPP-4 dipeptiyl peptidase 4 inhibitor, TZD
thiazolidlnedione, GLP-1 glucagon-like peptide 1 receptor agonist
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Avoiding increases in weight or body mass
index (BMI) (n = 116; 80.0%) and insulin
resistance (n = 96; 66.2%) were the most
commonly recorded reasons for selecting
dapagliflozin instead of intensifying insulin
treatment to achieve better glycemic control.
Reasons also included: patient choice (n = 46;
31.7%); risk of hypoglycemia (n = 39; 26.9%);
and other reasons (n = 37; 20.7%), of which
approximately half were other clinician’s
decision (n = 18) (Fig. 2).
Change in HbA1c Following Initiation
of Dapagliflozin
In patients with a recorded measurement, mean
HbA1c was lowered by 9.7 mmol/mol (95% CI
8.5–10.9) [0.89% (95% CI 0.78–0.99)]
14–90 days after starting dapagliflozin,
10.2 mmol/mol (95% CI 8.9–11.5) [0.93%
(95% CI 0.81–1.05)] after 91–180 days and
12.6 mmol/mol (95% CI 11.0–14.3) [1.16%
(95% CI 1.01–1.31)] beyond day 180 (Fig. 3a;
Supplementary material S3). This pattern of
greater reduction of HbA1c with longer
treatment was seen in most treatment
subgroups. Patients in the upper tertile of
baseline HbA1c (baseline C85 mmol/mol)
showed a greater reduction in HbA1c
[-17.7 mmol/mol (95% CI -20.1 to -15.4);
-1.62% (95% CI -1.84 to -1.41)] than those
with the lower tertile with baseline
B70 mmol/mol [-2.6 mmol/mol (95% CI -3.8
to -1.3); -0.24% (95% CI -0.35 to -0.12)]
14–90 days after the start of dapagliflozin
treatment (Fig. 3b). No differences were seen
in the pattern of HbA1c reductions when
stratified by baseline BMI (Fig. 3c).
Fig. 2 Reasons for use of dapagliﬂozin with insulin other than more/maximal intensiﬁcation
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Change in Body Weight Following
Initiation of Dapagliflozin
In patients with a recorded measurement, mean
weight loss was 2.6 kg (95% CI 2.3–2.9)
14–90 days after starting dapagliflozin, 4.3 kg
(95% CI 3.8–4.7) after 91–180 days and 4.6 kg
(95% CI 4.0–5.2) beyond 180 days (Fig. 4;
Supplementary material S4). This pattern of
greater weight loss after longer treatment
emerged in all subgroups stratified by
treatment. Patients receiving dual therapy
with metformin had a numerically greater
reduction in weight, which was not
statistically significant, than those who were
receiving insulin.
Change in Both HbA1c and Body Weight
Following Initiation of Dapagliflozin
In patients with measurements between 91 and
180 days after starting dapagliflozin (n = 347),
bFig. 3 a Changes in glycated hemoglobin (mmol/mol)
from baseline for each of the main treatment groups and
the entire cohort for the three follow-up periods; error bars
represent mean ± 95% conﬁdence interval. b Changes in
glycated hemoglobin (mmol/mol) from baseline by tertiles
of baseline glycated hemoglobin for the three follow-up
periods; error bars represent mean ± 95% conﬁdence
interval. c Changes in glycated hemoglobin (mmol/mol)
from baseline by categories of baseline body mass index for
the three follow-up periods; error bars represent
mean ± 95% conﬁdence interval
Fig. 3 continued
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63.1% had a decrease in both HbA1c and weight,
and only 3.2% had no decrease in either. Similar
results were observed in patients who had
follow-up beyond 180 days (n = 264), 68.2%
had decreases in both HbA1c and weight, and
only 2.3% had no decrease in either.
Regression analysis shows that the odds
of reaching an HbA1c target of
B58.5 mmol/mol (7.5%) is greatest in those
with an HbA1c \69.4 mmol/mol (8.5%) at
baseline (OR 12.63, CI 7.74–20.60; p\0.0001),
intermediate with HbA1c 69.4–85.8 mmol/mol
(8.5–10.0%) at baseline (OR 3.21, 95% CI
1.94–5.32; p\0.0001) compared to those
with an HbA1c [85.8 mmol/mol (10%)
(supplementary material S5).
Regression analysis also shows that the odds
of reaching an HbA1c target of B58.5 mmol/mol
(7.5%) is greatest in those who received
dapagliflozin for 181 days or longer (OR 2.29,
95% CI 1.26–4.14; p\0.0063). Those with a
baseline HbA1c \69.4 mmol/mol (8.5%) were
also more likely to reach a target of
B53.0 mmol/mol (7.0%) (OR 9.95, 95% CI
4.96–19.98; p\0.0001) than those with an
HbA1c [85.8 mmol/mol (10%). Weight loss of
C5% was more likely in those treated as dual
therapy [OR with metformin (OR 2.41, 95% CI
1.43–4.07; p\0.0001)] compared with insulin
treatment. Weight loss of C3% was also
associated with dual metformin therapy (OR
2.55, 95% CI 1.65–3.94; p\0.0001) and
treatment for 91 days or more (OR 1.81, 95%
CI 1.35–2.42; p\0.0001). Supplementary
material S5 and S6 provides details of the
regression analyses.
Fig. 4 Changes in body weight (kg) from baseline for each of the main treatment groups and the entire cohort for the three
follow-up periods; error bars represent mean ± 95% conﬁdence interval
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Change in Insulin Dose Following
Initiation of Dapagliflozin
In the 108 patients for whom sufficient
questionnaire data were recorded to assess
daily insulin dose at dapagliflozin initiation,
32 (29.6%) patients received long-acting insulin
only (mean 70.4 units, 95% CI 52.1–88.7), one
(0.9%) patient received short-acting insulin
only, and 75 (69.4%) received short- and
long-acting insulin either as a fixed mixture or
in a basal-bolus regimen (mean 106.2 units,
95% CI 90.6–121.8). The total average dose was
95.5 units (95% CI 83.1–107.9).
Following initiation of dapagliflozin, no
change in insulin dose was recorded for 36
patients (33.3%), with 19 patients (17.6%)
having an increase in insulin dose and 53
(49.1%) a decrease. In the 108 patients the
average insulin dose decreased by 14.8 units
(95% CI 8.0–21.6) following dapagliflozin
initiation. The average insulin dose decreased
by 8.3 units (95% CI 1.8–14.8) in patients with
long-acting insulin and 17.8 units (95% CI
8.4–27.2) in those with short-/long-acting
insulin.
Change in Blood Pressure Following
Initiation of Dapagliflozin
In patients with measurements between 14 and
90 days after starting dapagliflozin, systolic
(n = 416) and diastolic (n = 431) blood
pressure decreased by means of 4.5 (95% CI
3.2–5.8) mmHg and 2.0 (95% CI 1.2–2.9),
respectively from baseline. Similar reductions
in systolic and diastolic blood pressure were
observed after 91–180 days and when follow-up
extended beyond 180 days (Supplementary
material S7). In general, this pattern emerged
in all subgroups stratified by treatment. After
180 days, however, the reductions in blood
pressure were numerically smaller with dual
and triple therapy than when dapagliflozin was
added to insulin (Fig. 5a, b; Supplementary
material S7).
DISCUSSION
In this observational study of patients with T2D
initiated on dapagliflozin in primary care,
patients had a similar age and duration of T2D
to those in relevant clinical trials, but with
worse baseline glycemic control and higher
body weight. This pattern was seen
throughout the three treatment groups: a BMI
of 36.2 versus 31.2 kg/m2 and mean baseline
HbA1c of 76.5 mmol/mol (9.15%) versus
63.1 mmol/mol (7.92%) in patients prescribed
dapagliflozin in combination with metformin
(dual therapy) [1]; a BMI of 34.2 versus 32.0 kg/
m2 and mean baseline HbA1c of 78.8 mmol/mol
(9.36%) versus 66.6 mmol/mol (8.24%) for
patients receiving triple therapy [9]; and a BMI
of 35.8 versus 33.4 kg/m2 and mean baseline
HbA1c of 84.7 mmol/mol (9.90%) vs.
70.2 mmol/mol (8.57%) for patients who
received dapagliflozin as add-on to insulin
[10]. The basal and overall mean doses of
insulin in the present study (66.9, 95.5 units,
respectively) were higher than reported in the
RCTs (32.0, 78.0 units, respectively) [11]. The
reductions in HbA1c (9.7–12.6 mmol/mol;
0.89–1.16%), weight (2.6–4.6 kg) and blood
pressure (systolic 1.6–5.5 mmHg; diastolic
0.3–3.4 mmHg) after addition of dapagliflozin
in the present study were broadly consistent
with results from the dapagliflozin clinical trial
programme [1, 4–8, 10, 11].
Although an observational study population
will not map exactly to any RCT, there are
clinical trials in which patients were treated
with similar combinations of therapy to the
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most common treatment groups in our study.
First, for example, in patients treated with
metformin (C1500 mg per day), add-on of
dapagliflozin (10 mg) reduced HbA1c by
8.7 mmol/mol (unadjusted difference) (0.79%)
compared with 3.2 mmol/mol (0.30%) with
placebo after 24 weeks [1]. Second, in a
controlled trial, patients treated with
dapagliflozin added to metformin plus
sulfonylurea showed a placebo-subtracted
reduction in HbA1c of 7.5 mmol/mol (0.69%)
after 24 weeks [9]. Third, T2D patients who were
inadequately controlled by insulin with or
without other oral glucose-lowering drugs and
who received dapagliflozin, mean HbA1c
reductions at week 24 were 10.5 mmol/mol
(0.96%) with dapagliflozin 10 mg versus
4.3 mmol/mol (0.39%) with placebo [11]. The
reductions in HbA1c were similar in the present
study, which confirms the consistency of effects
of dapagliflozin in trial and the real world use.
The numerically greater decreases in HbA1c
observed in this real-world evidence study could
be explained in part by the higher baseline
values, this is consistently seen in most trials of
glucose-lowering treatments, irrespective of the
treatment used [1, 3, 9, 14]. The reasons in this
dataset may relate in part to greater glucosuria
at higher blood glucose levels and statistical
effects such as regression to the mean, although
the precise cause is not fully understood.
Reductions in HbA1c recorded after a longer
treatment with dapagliflozin were generally
larger than those recorded earlier in the course
of treatment, which again is consistent with
long-term controlled trials [5]. However, the
regression analysis shows that those patients
with lower HbA1c values before treatment were
more likely to reach targets of B58.5 mmol/mol
(7.5%) and B53.0 mmol/mol (7%) than those
with very high values. In addition, the
regression analysis suggested treatment for
181 days and longer was more likely to be
associated with the achievement of HbA1c
targets of B58.5 mmol/mol (7.5%), but might
also reflect a bias where patients who are
responding well are more likely to persist with
treatment. Older patients and those with very
long duration diabetes seemed less likely to
have a good HbA1c response. This might reflect
renal function, which declines with age and
duration of diabetes. However, renal function
was not assessed in the regression analysis.
In clinical trials, significant weight
reductions of 1.5–2.1 kg (placebo subtracted)
have been reported in patients treated with
dapagliflozin (10 mg) as add-on to metformin
with or without sulphonylurea or insulin over
24 weeks [1, 9, 11]. In longer studies, weight
appeared to stabilize after 24 weeks [4, 11]. The
present study observed weight reductions of
5.4 kg (add-on to metformin), 4.3 kg (triple
therapy) and 2.7 kg (add-on to insulin) at
3–6 months and greater reductions in patients
treated beyond 6 months (6.3, 4.4 and 3.2 kg,
respectively), numerically greater than those
seen in the RCT. This might be influenced by
the relatively high baseline values in our study:
McGovern et al. showed that a higher BMI at
baseline was associated with greater weight loss
[15]. In this study, BMI at baseline was not
associated with weight loss. However, weight
loss of C3 and C5% was associated with
treatment with dapagliflozin for 91 days or
longer, and with dual therapy with
dapagliflozin and metformin.
bFig. 5 a Changes in blood pressure (mmHg) from baseline
for each of the main treatment groups and the entire
cohort for the three follow-up periods; error bars represent
mean ± 95% conﬁdence interval. b Changes in blood
pressure stratiﬁed by baseline blood pressure; for the three
follow-up periods; error bars represent mean ± 95%
conﬁdence interval
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Hypertension is common in T2D patients
and further increases the risk of micro vascular
and macro vascular complications [16]. The
reductions in BP associated with dapagliflozin
in the present study (systolic 1.6–5.5 mmHg;
diastolic 0.3–3.4 mmHg) are similar in the
entire population and in subgroups stratified
by treatment. The findings are broadly
consistent with other studies. Weber et al.
assessed dapagliflozin in patients with
uncontrolled T2D and hypertension.
Dapagliflozin was associated with greater
reductions in systolic blood pressure compared
to placebo (adjusted mean change from baseline
-11.90 and -7.62 mmHg, respectively;
placebo-adjusted difference 4.28 mmHg) [16].
The smaller reduction in the present study
presumably reflects the population, of whom
only 58% had hypertension.
The median duration of therapy in this
study was 10.8 months, consistent with an
acceptable tolerability profile; however, no
data were collected on tolerability. In a
previous clinical study, 15.4% of patients
receiving dapagliflozin (10 mg daily) added to
metformin and 4.4% of those taking placebo
and metformin discontinued due to adverse
events during 102 weeks’ treatment [5]. An
observational hospital study reported that 22%
of patients discontinued dapagliflozin due to
side effects and 52% stopped or reduced the
dose of at least one other diabetes medication
[15].
Whereas limited external validity
compromises many large trials of glycemic
control among T2D patients [12], the CPRD
database captures a representative sample of the
UK population of over 12 million people [13]
from 680 general practices. The present
alignment of data from our observational
study with those from RCT suggests that the
findings are robust and could be generalized to a
UK primary care population. The effects of
dapagliflozin initiation in secondary hospital
care settings were assessed by a small
observational study by McGovern et al. in 96
T2D patients, 42% of their population showed a
reduction of C1% in HbA1c, 15% showed weight
loss C5 kg and 3% showed weight loss C10 kg
[15]. These improvements in HbA1c, weight and
blood pressure were consistent with those
reported in clinical trials [15].
The present results confirm the multiple
patient factors beyond poor glycemic control
per se that contribute to the decision to
prescribe dapagliflozin to insulin-treated
patients, particularly insulin resistance,
avoidance of weight gain and hypoglycemia.
Our study is associated with several
limitations, largely reflecting the source of the
data. For example, clinicians may vary in the
time since last HbA1c measurement when they
move patients to the next treatment step, the
detail with which they complete clinical
measures and the information added to the
records. There is evidence from a systematic
review that 15–33% of diabetes patients are
non-adherent with oral glucose-lowering
therapy [17]. However, as CPRD records that a
prescription was issued, not whether it was
dispensed or taken by the patient, we are unable
to assess adherence in our population. It is likely
that the results reported were achieved despite
potentially higher levels of non-adherence
compared with an RCT population. In
addition, CPRD does not capture medicines
prescribed in secondary care. Therefore, the
first dapagliflozin prescription entered in
CPRD may not be the first time the patient
received the drug. This would tend to
underestimate changes in HbA1c and weight
associated with dapagliflozin in primary care.
The results of the GP questionnaire might be
subject to selection and recollection bias,
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especially if the reasons for adding dapagliflozin
are not clearly documented in the notes. Since
this is a descriptive study without a comparative
arm, any changes observed may not relate to
dapagliflozin alone. As such, the results must be
regarded as hypothesis generating although
they are consistent with the Phase 3 clinical
evidence. Because this analysis is mostly
concerned with the initial year of treatment
with dapagliflozin, it is not possible from these
data to predict therapeutic persistence.
Finally, another limitation of this study is
that adverse events were not examined. Adverse
events like hypoglycemia are likely to be
underestimated in a primary care database due
to missing detailed clinical information. We
would need to examine anonymized free text
entered by the GP or send out questionnaires to
GPs. Free text has not been available in CPRD
since mid-2013 and approximately 90% of our
cohort initiated dapagliflozin after June 2013.
Furthermore, most patients not on insulin are
not advised to self-monitor blood glucose so
may not detect minor hypoglycemic episodes if
they occur. Many hypoglycemic episodes are
treated by ambulance crews without hospital
admission and this information is not captured
in the GP record [18]. The majority of patients
in this study were not prescribed insulin.
Secondary care data would be required to
identify severe hypoglycemic events leading to
hospitalizations. Although, CPRD primary care
data can be linked to secondary care data, there
is incomplete linkage and a lag in follow-up.
The lag in follow-up is a particular problem
when examining medications which have a
relatively recent launch date like dapagliflozin.
Rates of hypoglycemia in RCTs when
dapagliflozin was added to metformin or used
as monotherapy were similar to placebo [1]; and
over 2 years there was also no difference when
used in combination with insulin [19].
CONCLUSION
This first observational study in patients treated
with dapagliflozin in primary care practice in
the UK found that HbA1c weight and blood
pressure were reduced after initiation of
dapagliflozin, and this is consistent with
results from the dapagliflozin clinical trial
programme.
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